Cyclosporin in the treatment of severe chronic idiopathic uveitis

J de Vries, G S Baarsma, M J Zaal, T N Boen-Tan, A Rothova, H J Buitenhuis, C M Schweitzer, R J de Keizer, A Kijlstra

Research output: Contribution to journalArticleResearchpeer-review


In a randomised double-masked study of 27 patients with a severe chronic idiopathic uveitis we evaluated the efficacy, safety, and tolerability of cyclosporin. All received prednisone in a low dose (0.3 mg/kg/day). In 14 patients this was combined with cyclosporin in a single daily dose of 10 mg/kg/day, while 13 patients received a placebo. The dosages were tapered off in accordance with a protocol, and we compared the number of months of successful therapy before the uveitis relapsed. The efficacy results, as expressed in a Kaplan-Meier curve, were in favour of cyclosporin. Owing to the small sample size, however, this difference did not reach statistical significance. The immunosuppressive effect of cyclosporin was not permanent, and in all but one patient the intraocular inflammation relapsed on reduction of dosage. Rather small cumulative doses of cyclosporin proved to be nephrotoxic, but subjective tolerability for cyclosporin was good.

Original languageEnglish
Pages (from-to)344-9
Number of pages6
JournalBritish Journal of Ophthalmology
Issue number6
Publication statusPublished - Jun 1990


  • Adult
  • Aged
  • Chronic Disease
  • Cyclosporins/adverse effects
  • Double-Blind Method
  • Drug Tolerance
  • Female
  • Humans
  • Male
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Uveitis/drug therapy


Dive into the research topics of 'Cyclosporin in the treatment of severe chronic idiopathic uveitis'. Together they form a unique fingerprint.

Cite this